کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
8536499 | 1666232 | 2018 | 7 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
Pharmacological intervention in hypertension using beta-blockers: Realâworld evidence for long-term effectiveness
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
کلمات کلیدی
موضوعات مرتبط
علوم پزشکی و سلامت
داروسازی، سم شناسی و علوم دارویی
داروشناسی
پیش نمایش صفحه اول مقاله
![عکس صفحه اول مقاله: Pharmacological intervention in hypertension using beta-blockers: Realâworld evidence for long-term effectiveness Pharmacological intervention in hypertension using beta-blockers: Realâworld evidence for long-term effectiveness](/preview/png/8536499.png)
چکیده انگلیسی
The study objective was to compare the long-term incidence and risk of mortality and cardiovascular outcomes in patients with hypertension initiating bisoprolol, other β-blockers or other antihypertensive therapies. Cohort analysis using UK Clinical Practice Research Datalink (CPRD). Adult patients with first diagnosis of hypertension recorded between 2000 and 2014, with â¥365â¯days of registration to first event and initiating monotherapies of bisoprolol, other β-blockers or drugs other than β-blockers within 6 months of diagnosis were included. Incidence rates (IR) for each treatment cohort were compared using adjusted hazard ratio (HR) and 95% confidence intervals (CI) obtained from Cox regression analyses. Of 100,066 patients included, 539 were prescribed bisoprolol, 3701 other β-blockers, and 95,826 drugs other than βâblockers. Patients receiving bisoprolol had significantly increased survival from 2 up to <15 years (HR for <15 years 0.34; 95% CI 0.18-0.67) versus other βâblockers, and from 5 to <15âyears (HR for <15âyears 0.52; 95% CI 0.27-1.00) versus drugs other than βâblockers. Over time, the risk of arrhythmia was higher in the bisoprolol cohort versus other βâblockers, and risks of arrhythmia and angina were higher versus drugs other than βâblockers. No differences in the risk of embolism, stroke, and myocardial infarction (MI) were found between cohorts. Over time, mortality and cardiovascular outcome IRs decreased in each cohort. In conclusion, bisoprolol showed sustained benefit on survival, evident from 2 years after treatment initiation versus other βâblockers, and from 5 years versus drugs other than βâblockers, providing long-term evidence supporting the use of bisoprolol in patients with hypertension in primary care.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Pharmacological Research - Volume 130, April 2018, Pages 191-197
Journal: Pharmacological Research - Volume 130, April 2018, Pages 191-197
نویسندگان
Meritxell Sabidó, Thilo Hohenberger, Guido Grassi,